Alzheimer's disease (AD) and age-related macular degeneration (AMD) are two common neurodegenerative diseases with many similar pathological features, but their shared metabolic characteristics have not been fully elucidated.
Objective
This study aims to explore the shared metabolic pathways between AD and AMD using an integrated multi-omics strategy.
Methods
We incorporated Mendelian randomization (MR), bulk and single-cell transcriptomics, and targeted metabolomics to investigate the metabolic links.
Results
Through MR, we found elevated genetically inferred glutamine concentrations were correlated with a lower likelihood of AD but a higher likelihood of AMD. Using transcriptomic profiling, we detected 19 common differentially expressed genes associated with glutamine and glutamate metabolism, such as GLS. Analysis of single-cell RNA sequencing data revealed that GLS displays distinct cell-type expression patterns. Targeted metabolomic profiling in APP/PS1 mice at 5 months of age provided additional evidence for alterations in glutamine metabolism. The degree of metabolic changes in the eyes was higher than that in the cortex and hippocampus, and the prominent eyes may be an early indicator of neurodegenerative metabolic dysfunction.
Conclusions
Overall, these findings suggest that glutamine metabolism disorders represent a convergent mechanism between AD and AMD. Our findings shed light on the overlapping metabolic pathways linking AD and AMD, underscoring the value of ocular biomarkers as promising tools for early disease detection.
GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health2022; 7: e105–e125.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer’s disease. Lancet2021; 397: 1577–1590.
4.
DuboisBFeldmanHHJacovaC, et al.Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol2007; 6: 734–746.
5.
DeTureMADicksonDW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener2019; 14: 32.
6.
CummingsJLeeGNahedP, et al.Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement (N Y)2022; 8: e12295.
7.
ChaudhuriMHassanYBakka VemanaPPS, et al.Age-related macular degeneration: an exponentially emerging imminent threat of visual impairment and irreversible blindness. Cureus2023; 15: e39624.
8.
DengYQiaoLDuM, et al.Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis2022; 9: 62–79.
9.
WongJHCMaJYWJoblingAI, et al.Exploring the pathogenesis of age-related macular degeneration: a review of the interplay between retinal pigment epithelium dysfunction and the innate immune system. Front Neurosci2022; 16: 1009599.
10.
HandaJTBowes RickmanCDickAD, et al.A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. Nat Commun2019; 10: 3347.
11.
HadziahmetovicMMalekG. Age-related macular degeneration revisited: from pathology and cellular stress to potential therapies. Front Cell Dev Biol2020; 8: 612812.
12.
Ochoa HernándezMELewis-LujánLMBurboa ZazuetaMG, et al.Role of oxidative stress and inflammation in age related macular degeneration: insights into the retinal pigment epithelium (RPE). Int J Mol Sci2025; 26: 3463.
13.
HouX-WWangYPanC-W. Metabolomics in age-related macular degeneration: a systematic review. Invest Ophthalmol Vis Sci2020; 61: 13.
14.
TangSYangJXiaoB, et al.Aberrant lipid metabolism and complement activation in age-related macular degeneration. Invest Ophthalmol Vis Sci2024; 65: 20.
15.
XuQCaoSRajapakseS, et al.Understanding AMD by analogy: systematic review of lipid-related common pathogenic mechanisms in AMD, AD, AS and GN. Lipids Health Dis2018; 17: 3.
16.
MoQLiuXGongW, et al.Pinpointing novel plasma and brain proteins for common ocular diseases: a comprehensive cross-omics integration analysis. Int J Mol Sci2024; 25: 10236.
17.
KohnoMMusashiKIkedaHO, et al.Oral administration of ferulic acid or ethyl ferulate attenuates retinal damage in sodium iodate-induced retinal degeneration mice. Sci Rep2020; 10: 8688.
18.
WangWZhaoFMaX, et al.Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances. Mol Neurodegener2020; 15: 30.
19.
Flores-LeonMOuteiroTF. More than meets the eye in Parkinson’s disease and other synucleinopathies: from proteinopathy to lipidopathy. Acta Neuropathol (Berl)2023; 146: 369–385.
20.
KapogiannisDMattsonMP. Perturbed energy metabolism and neuronal circuit dysfunction in cognitive impairment. Lancet Neurol2011; 10: 187–198.
21.
TongBBaYLiZ, et al.Targeting dysregulated lipid metabolism for the treatment of Alzheimer’s disease and Parkinson’s disease: current advancements and future prospects. Neurobiol Dis2024; 196: 106505.
22.
TangSYangJXiaoB, et al.Aberrant lipid metabolism and complement activation in age-related macular degeneration. Invest Ophthalmol Vis Sci2024; 65: 20.
23.
PolisBSamsonAO. Role of the metabolism of branched-chain amino acids in the development of Alzheimer’s disease and other metabolic disorders. Neural Regen Res2020; 15: 1460–1470.
24.
LiuRZhangLYouH. Insulin resistance and impaired branched-chain amino acid metabolism in Alzheimer’s disease. J Alzheimers Dis JAD2023; 93: 847–862.
25.
XiaMZhangF. Amino acids metabolism in retinopathy: from clinical and basic research perspective. Metabolites2022; 12: 1244.
26.
HouX-WWangYPanC-W. Metabolomics in age-related macular degeneration: a systematic review. Invest Ophthalmol Vis Sci2020; 61: 13.
27.
Davey SmithGHemaniG. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet2014; 23: R89–R98.
28.
ChenYLuTPettersson-KymmerU, et al.Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. Nat Genet2023; 55: 44–53.
29.
ZhouJHongHZhaoJ, et al.Metabolome analysis to investigate the effect of heavy metal exposure and chemoprevention agents on toxic injury caused by a multi-heavy metal mixture in rats. Sci Total Environ2024; 906: 167513.
30.
AdamsCD. Circulating glutamine and Alzheimer’s disease: a Mendelian randomization study. Clin Interv Aging2020; 15: 185–193.
31.
HuangS-YYangY-XZhangY-R, et al.Investigating causal relations between circulating metabolites and Alzheimer’s disease: a Mendelian randomization study. J Alzheimers Dis2022; 87: 463–477.
32.
WeiPGaoSHanG. Evidence for genetic causal association between the gut microbiome, derived metabolites, and age-related macular degeneration: a mediation Mendelian randomization analysis. Biomedicines2025; 13: 639.
AlbrechtJSidoryk-WęgrzynowiczMZielińskaM, et al.Roles of glutamine in neurotransmission. Neuron Glia Biol2010; 6: 263–276.
35.
SoaresCDa RosLUMachadoLS, et al.The glutamatergic system in Alzheimer’s disease: a systematic review with meta-analysis. Mol Psychiatry2024; 29: 2261–2273.
36.
ChenYXiaQZengY, et al.Regulations of retinal inflammation: focusing on Müller glia. Front Cell Dev Biol2022; 10: 898652.
37.
DingLXuXLiC, et al.Glutaminase in microglia: a novel regulator of neuroinflammation. Brain Behav Immun2021; 92: 139–156.
38.
JesudasanSJBGuptaSJChurchwardMA, et al.Inflammatory cytokine profile and plasticity of brain and spinal microglia in response to ATP and glutamate. Front Cell Neurosci2021; 15: 634020.
39.
TeleginaDVAntonenkoAKFursovaAZ, et al.The glutamate/GABA system in the retina of male rats: effects of aging, neurodegeneration, and supplementation with melatonin and antioxidant SkQ1. Biogerontology2022; 23: 571–585.
40.
GoswamiMTWehESubramanyaS, et al.Glutamine catabolism supports amino acid biosynthesis and suppresses the integrated stress response to promote photoreceptor survival. Elife2025; 13: RP100747.
41.
TamsALMSanz-MorelloBWestiEW, et al.Decreased glucose metabolism and glutamine synthesis in the retina of a transgenic mouse model of Alzheimer’s disease. Cell Mol Neurobiol2022; 42: 291–303.
42.
PatelABTiwariVVeeraiahP, et al.Increased astroglial activity and reduced neuronal function across brain in AβPP-PS1 mouse model of Alzheimer’s disease. J Cereb Blood Flow Metab2018; 38: 1213–1226.
43.
ZhouQZhengHChenJ, et al.Metabolic fate of glucose in the brain of APP/PS1 transgenic mice at 10 months of age: a 13C NMR metabolomic study. Metab Brain Dis2018; 33: 1661–1668.
44.
NilsenLHWitterMPSonnewaldU. Neuronal and astrocytic metabolism in a transgenic rat model of Alzheimer’s disease. J Cereb Blood Flow Metab2014; 34: 906–914.
45.
AksenovMYAksenovaMVCarneyJM, et al.Oxidative modification of glutamine synthetase by amyloid beta peptide. Free Radic Res1997; 27: 267–281.
46.
BornsteinRMulhollandMTSedenskyM, et al.Glutamine metabolism in diseases associated with mitochondrial dysfunction. Mol Cell Neurosci2023; 126: 103887.
47.
NewsholmePDinizVLSDoddGT, et al.Glutamine metabolism and optimal immune and CNS function. Proc Nutr Soc2023; 82: 22–31.
48.
ZhengHZhouQDuY, et al.The hypothalamus as the primary brain region of metabolic abnormalities in APP/PS1 transgenic mouse model of Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis2018; 1864: 263–273.
49.
TakeuchiAIrizarryMCDuffK, et al.Age-related amyloid β deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid β precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol2000; 157: 331–339.
50.
HunsbergerHCGreenwoodBPTolstikovV, et al.Divergence in the metabolome between natural aging and Alzheimer’s disease. Sci Rep2020; 10: 12171.
51.
RheinVSongXWiesnerA, et al.Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice. Proc Natl Acad Sci U S A2009; 106: 20057–20062.
52.
WilkinsJMTrushinaE. Application of metabolomics in Alzheimer’s disease. Front Neurol2017; 8: 719.
53.
Castro-GomezSHenekaMT. Innate immune activation in neurodegenerative diseases. Immunity2024; 57: 790–814.
ChoiSJahngWJParkSM, et al.Association of age-related macular degeneration on Alzheimer or Parkinson disease: a retrospective cohort study. Am J Ophthalmol2020; 210: 41–47.
56.
RongSSLeeBYKukAK, et al.Comorbidity of dementia and age-related macular degeneration calls for clinical awareness: a meta-analysis. Br J Ophthalmol2019; 103: 1777–1783.
57.
FengJHuangCLiangL, et al.The association between eye disease and incidence of dementia: systematic review and meta-analysis. J Am Med Dir Assoc2023; 24: 1363–1373.e6.
58.
SaddaSRGuymerRHolzFG, et al.Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3. Ophthalmology2018; 125: 537–548.
59.
BarthélemyNRSalvadóGSchindlerSE, et al.Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med2024; 30: 1085–1095.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
